In part 2 of our series on incretin mimetics, we cover the growth of GLP-1 analogues in obesity

In the third and final part of our series on incretin mimetics, we address pharma’s efforts to overcome supply and pricing issues

This three-part series will dig into incretin mimetics, their rise to fame in weight management and what it will take for the drug class to truly transform obesity care

How data mesh can help the pharma industry free data from silos